Stockscreener 앱 받기
1.78
2.73%
-0.05
시간 외 거래:
1.76
-0.02
-1.12%
전일 마감가:
$1.83
열려 있는:
$1.81
하루 거래량:
128.20K
Relative Volume:
0.11
시가총액:
$10.98M
수익:
$93.76M
순이익/손실:
$-13.68M
주가수익비율:
-0.6768
EPS:
-2.63
순현금흐름:
$8.77M
1주 성능:
-9.18%
1개월 성능:
+66.36%
6개월 성능:
+10.56%
1년 성능:
-42.77%
1일 변동 폭
$1.76
$1.84
1주일 범위
$1.76
$2.01
52주 변동 폭
$0.95
$3.23
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
AYTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.78 | 12.09M | 93.76M | -13.68M | 8.77M | -2.63 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World
Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus
Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India
Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView
Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - ACCESS Newswire
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire
Aytu BioPharma at Planet MicroCap: Strategic Realignment and Growth By Investing.com - Investing.com Canada
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS - GuruFocus
Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 | AYTU Stock News - GuruFocus
Aytu BioPharma CEO Reveals Growth Strategy at Exclusive Vegas Investor Showcase - Stock Titan
Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director - ACCESS Newswire
AYTU stock touches 52-week low at $1.13 amid market challenges - Investing.com India
Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire
AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia
Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com
Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
18.36%
0.52%
자본화:
|
볼륨(24시간):